27 Jan 2010 The Peninsula
 

Anti-obesity pill banned

  • Text size
  •  
  •  

DOHA: The Supreme Council of HealthSupreme Council of HealthLoading... (SCHSCHLoading...) has banned the use and sale of Reductil Sibutramine, a popular anti-obesity pill in the country, due to its potential health hazards.

The product is manufactured by the German company, Abbott. The decision was taken on the recommendation of the European Medicines Agency, which recently warned that the medicine could increase the patient's chances of suffering a heart attack or stroke.

An official at the Drugs Control Department at SCHSCHLoading... told The Peninsula yesterday that a circular had been sent to all pharmacies asking them to stop selling the product.

The move suspending the sale of the medicine, however, fell short of a total ban, said the official.

In a statement issued yesterday, the SCHSCHLoading... warned the public against using the medicine and called on companies not to import it.

The EMA recently ordered doctors across the continent to stop prescribing sibutramine and told pharmacists not to dispense the drug, which is marketed in many countries as Reductil ().

The watchdog's Committee for Medicinal Products for Human Use (CHMP) acted after a study of 9,800 patients said the risks of using sibutramine outweighed its minimal benefits.

About 86,000 people took the drug last year. It is prescribed for patients who are classed as clinically obese because they have a Body Mass Index of at least 30, and also for profoundly overweight people who also have a condition such as type 2 diabetes or abnormal levels of fat in their blood.

Enquiries with some pharmacies in Doha last evening revealed that the pills were still available with them.

"We have not received any instructions from the health authorities until now," said a pharmacist in the Airport area.

He said Reductil was one of the commonly prescribed anti-obesity pills in Qatar. The medicine had been sold over the counter until a doctor's prescription was made compulsory by the health authorities some years ago, he added.

The tablet is available in 10mg and 15mg sachets that are priced at QR257 and QR291, respectively.

Recently, the Supreme Council of HealthSupreme Council of HealthLoading... (SCHSCHLoading...) warned the public against using a herbal medicine Quick Acting Slimming Capsule manufactured by a Lebanon-based company specialising in herbal products. The product is not licensed in Qatar but some people were bringing it from abroad for personal use.

By Mohammed Iqbal

© The Peninsula 2010

x DISCLAIMER

Zawya is a distributor (and not a publisher) of content supplied by third parties and subscribers. Any opinions, advice, statements, services, offers, or other information or content expressed or made available by those third parties, including information providers, subscribers or other users of the Service, are those of the respective author(s) or distributor(s) and not of the Company. The Company neither endorses nor is responsible for the accuracy or reliability of any opinion, advice or statement made on the Service by anyone other than authorized Service employee spokespersons while acting in their official capacities. The Company is not responsible for any infringement of intellectual property rights or breach of any applicable law or regulation, including regulation in relation to financial services or the distribution of financial products, defamation, data protection, telecommunications (including regulations relating to excessive use, spamming or other abusive activities) or obscene, offensive or illegal content). Under no circumstances will the Company be liable for any loss or damage caused by a member's reliance on information obtained through the Service. It is the responsibility of member to evaluate the accuracy, completeness or usefulness of any information, opinion, advice or other content available through the Service. Please seek the advice of professionals, as appropriate, regarding the evaluation of any specific information, opinion, advice or other content.

Read the full Member Agreement
http://www.zawya.com/legal/NewsLetter.cfm?name=disclaimer
Access to this article is subject to specific terms and condition.
 
 

Post a Comment

 
  • Comment Title (optional)
  • Express your views or tell us more about this article
  • First Name
  • Last Name
  • Email Address
  • Company Name (optional)
Leave this field empty
 
 
Zawya Comment Policy
 
  1. Zawya encourages you to add a comment to this discussion. You agree that when you add content to this discussion your comments will not:
    1.1   Contain any material which is libelous or defamatory of any person, is obscene, offensive, hateful or inflammatory or causes damage to the reputation of any person or organisation.
    1.2   Promote sexually explicit material, violence, discrimination based on race, sex, religion, nationality, disability, sexual orientation or age or any illegal activity.
    1.3   Be made in breach of any legal duty owed to a third party, such as a contractual duty or a duty of confidence.
    1.4   Be threatening, abuse or invade another's privacy, or cause annoyance, inconvenience or needless anxiety.
    1.5   Be used to impersonate any person, to misrepresent your identity or affiliation with any person, or be likely to deceive any person.
    1.6   Give the impression that they represent Zawya.
    1.7   Advocate, promote or assist any unlawful act such as (by way of example only) copyright infringement or computer misuse.
  2. The content posted on www.zawya.com is created by members of the public. The views expressed are theirs and unless specifically stated are not those of Zawya. Zawya reserves the right to review all comments prior to posting and edit or delete any contribution, but Zawya is not responsible for and can not be held liable for any content posted by members of the public on www.zawya.com.
  3. Zawya is not responsible for the availability or content of any third party sites that are accessible through www.zawya.com. Any links to third party websites from www.zawya.com do not amount to any endorsement of that site by Zawya and any use of that site by you is at your own risk.
  4. By submitting your comment, you hereby give Zawya the right, but not the obligation, to post, air, edit, exhibit, telecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comments worldwide, in perpetuity.